Using SCALE-EYE to measure colorectal polyp size accurately and reduce procedure waste
Official title: Diagnostic Performance and Sustainability of Using SCALE-EYE During Real-Time Colonoscopy
Run by Erasmus Medical Center · NCT07005453 · Data updated 2026-11-12
This trial tests whether SCALE-EYE can accurately measure polyp size during screening or surveillance colonoscopy in people aged 55–80 and whether its use can cut down on follow-up procedures and waste.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 55 Years to 80 Years |
| Sex | All |
| Enrollment | 241 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Eindhoven, North Brabant and 2 other locations) |
| Status | Recruiting |
| Started | September 23, 2025 |
| Main results expected | February 1, 2026 |
| Study ends | April 1, 2026 |
| Registry record updated | January 13, 2026 |
| Trial ID | NCT07005453 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults aged 55–80 scheduled for FIT screening or surveillance colonoscopy who consent and have one or more colorectal polyps ≤25 mm detected during the procedure.
✕Probably not a fit
Patients who have no detected polyps, only diminutive (≤5 mm) hyperplastic rectal polyps, inadequate bowel preparation, known IBD, polyposis syndromes, or other listed exclusions are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, randomized, parallel-group, endoscopist-blinded study comparing SCALE-EYE measurements to biopsy-forceps assisted measurement and standard optical assessment during real-time screening and surveillance colonoscopies. The unit of analysis is the colorectal polyp, with about 289 polyps expected from roughly 241 participants aged 55–80 who are referred for FIT screening or surveillance colonoscopy. Polyps under 25 mm of any shape detected during colonoscopy will be measured first by the endoscopist's optical estimate and then, in randomized order, by biopsy-forceps assisted measurement and SCALE-EYE. The study also quantifies sustainability outcomes including reductions in colonoscopies, associated waste, and carbon footprint if SCALE-EYE changes management.
Why it matters
Potential benefit: If successful, SCALE-EYE could improve polyp sizing accuracy, potentially reducing unnecessary polypectomies and follow-up colonoscopies while lowering medical waste and carbon emissions.
How similar studies have gone: Prior pilot and single-center work on optical and virtual measuring tools has shown promising accuracy, but a multicenter randomized, blinded comparison of SCALE-EYE is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants aged 55-80 * Scheduled for fecal immunochemical test (FIT) screening or surveillance colonoscopy * Polyps of all forms ≤25 mm as assessed by the endoscopist Exclusion Criteria: * No detected colorectal polyps or only diminutive (≤5 mm) hyperplastic rectal polyps are present * Inadequate bowel preparation (Boston Bowel Preparation Score (BBPS) \<2 per segment) * Intraprocedural complications, not caused by the study device * Known or suspected inflammatory bowel disease (IBD) * Polyposis syndromes (e.g. serrated polyposis, familial adenomatous polyposis) * Ileoanal pouch and anastomosis * History of radiation or chemotherapy for colorectal lesions * Scheduled for therapeutic procedure (for example intervention to stop a lower gastro-intestinal bleeding, endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)) * Pregnancy * No Informed consent (IC) possible
Where it's running
-
Catharina Ziekenhuis
Eindhoven, North Brabant, Netherlands Recruiting -
Lumc
Leiden, South Holland, Netherlands Recruiting -
Erasmus MC
Rotterdam, South Holland, Netherlands Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Post-polypectomy scar: comparing four imaging methods to find residual tissue
Doctors will test four imaging methods to see which best detects leftover or recurrent tissue at colonoscopy scars after large polyps were removed.
-
Noninvasive molecular test for colorectal polyps before colonoscopy
This study tests whether saliva and stool markers can predict the presence of colorectal polyps in adults undergoing colonoscopy.
-
SUBMO for Submucosal Injection in Endoscopic Resection of Colorectal Polyps
This trial tests whether SUBMO®, a hyaluronic acid-based gel with blue dye, can safely and effectively replace saline for submucosal injection during endoscopic removal of colorectal polyps larger than 10 mm.
-
Digital training to improve optical diagnosis of colorectal polyps
This project will test whether a digital training app helps doctors more accurately predict polyp tissue type during colonoscopy for adults who have polyps.
-
3D imaging during colonoscopy to find high-risk adenomas
This trial tests whether a 3D imaging device used during colonoscopy helps identify patients with high-risk adenomas better than standard 2D imaging.
-
Using AI to predict polyp pathology during colonoscopy
This study is testing whether a new AI tool can help doctors better identify and classify polyps during colonoscopy to improve patient care and reduce unnecessary procedures.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.